News

Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 20.3% year on year to $158.7 million. The company’s full-year revenue guidance of $695 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP loss of $0.95 per share was 1.5% below analysts’ consensus estimates.

Outerwear manufacturer Columbia Sportswear (NASDAQ:COLM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 1.1% year on year to $778.5 million. On the other hand, next quarter’s revenue guidance of $587.5 million was less impressive, coming in 2.9% below analysts’ estimates. Its GAAP profit of $0.75 per share was 9.7% above analysts’ consensus estimates.

Digital transformation consultancy Grid Dynamics (NASDAQ:GDYN) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 25.8% year on year to $100.4 million. The company expects next quarter’s revenue to be around $101 million, close to analysts’ estimates. Its non-GAAP profit of $0.11 per share was 24.9% above analysts’ consensus estimates.

US stocks likely hit a peak relative to the rest of global markets on Christmas Eve last year, Jefferies' top stock strategist said.

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be around $4.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.32 per share was in line with analysts’ consensus estimates.

IT project management software company, Atlassian (NASDAQ:TEAM) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.1% year on year to $1.36 billion. The company expects next quarter’s revenue to be around $1.35 billion, close to analysts’ estimates. Its non-GAAP profit of $0.97 per share was 4.9% above analysts’ consensus estimates.

Online payroll and human resource software provider Asure (NASDAQ:ASUR) announced better-than-expected revenue in Q1 CY2025, with sales up 10.1% year on year to $34.85 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $31 million was less impressive, coming in 2.2% below expectations. Its GAAP loss of $0.09 per share was 40.6% below analysts’ consensus estimates.